Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Faces Nasdaq Delisting for Sub-Dollar Share Price

This article has been updated from a previous version to reflect today's morning trading.


NEW YORK, June 22 (GenomeWeb News) - Genaissance has received a letter from Nasdaq warning that it faces delisting for failure to meet minimum trading requirements, the company said in an SEC filing yesterday.


Genaissance, which announced on Tuesday that it has entered into an agreement to be acquired by diagnostic firm Clinical Data, said that it received notification from Nasdaq yesterday that its share price for the last 30 consecutive trading days had closed below the minimum $1.00 per share required for continued listing.


Genaissance said it has 180 calendar days, or until Dec. 19, to regain compliance. To do this, its stock must close at or above $1.00 per share for a minimum of ten consecutive trading days.


The company's stock closed at $1.06 on June 20, and $1.16 on June 21. As of this morning's trading, the company's share price was $1.18.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.